Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. [electronic resource]
Producer: 20190415Description: 1292 p. digitalISSN:- 1471-2407
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Carcinoma, Ovarian Epithelial -- drug therapy
- Cisplatin -- pharmacology
- Constipation -- chemically induced
- Doxorubicin -- analogs & derivatives
- Drug Resistance, Neoplasm
- Fatigue -- chemically induced
- Female
- Humans
- Middle Aged
- Mucositis -- chemically induced
- Nausea -- chemically induced
- Neoplasm Recurrence, Local -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Polyethylene Glycols -- pharmacology
- Progression-Free Survival
- Receptor, Platelet-Derived Growth Factor alpha -- antagonists & inhibitors
- Time Factors
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.